A Clinical Trial Evaluating IL-22BP/LNP Compound in Refractory Malignant Solid Tumors for Safety, Tolerability and Activity

Clinical trial NCT07100210 · RECRUITING

Trial details

NCT number: NCT07100210
Sponsor: Xingchen Peng
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Refractory Malignant Solid Tumors mRNA Vaccine Interleukin

Start date: 2025-01-20
Primary completion: 2026-02-20
Enrollment: 6

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.